The Roche group’s monoclonal antibody, Avastin (bevacizumab), has failed to reach its primary endpoint in a second Phase 3 trial in early-stage colon cancer. The primary endpoint was disease-free survival in patients with stage 3 colon cancer. ---Subscribe to MedNous to access this article--- Company News
